AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Iovance Biotherapeutics to Announce Q2 and H1 2025 Financial Results and Corporate Updates on August 7, 2025
ByAinvest
Thursday, Jul 24, 2025 4:08 pm ET1min read
Iovance Biotherapeutics will report Q2 and H1 2025 financial results and corporate updates on August 7, 2025. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update. The company's Amtagvi is the first FDA-approved T cell therapy for a solid tumor indication. Iovance is focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte therapies for patients with cancer.
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a leading biotechnology company specializing in tumor infiltrating lymphocyte (TIL) therapies for cancer treatment, has scheduled its second quarter and first half 2025 financial results announcement for August 7, 2025. The company will host a conference call and webcast at 4:30 p.m. ET to discuss financial performance and provide corporate updates.The financial results and corporate updates will be hosted on Thursday, August 7, 2025, at 4:30 p.m. ET. Investors can access the webcast through the company's website at IR.Iovance.com, with the recording remaining available for one year.
Iovance Biotherapeutics is committed to innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte therapies for patients with cancer. The company's Amtagvi is the first FDA-approved T cell therapy for a solid tumor indication. Management will discuss the company's financial performance, recent clinical trial outcomes, and strategic initiatives during the conference call.
The appointment of Corleen Roche as Chief Financial Officer, effective August 6, 2025, signifies renewed strategic financial priorities for Iovance. Additionally, positive real-world outcomes for Amtagvi in advanced melanoma have boosted investor optimism for future growth.
For more information, please visit [1] https://www.stocktitan.net/news/IOVA/iovance-biotherapeutics-to-host-second-quarter-and-first-half-2025-o63578qsktjp.html [2] https://www.timothysykes.com/news/iovance-biotherapeutics-inc-iova-news-2025_07_23/.
References:
[1] https://www.stocktitan.net/news/IOVA/iovance-biotherapeutics-to-host-second-quarter-and-first-half-2025-o63578qsktjp.html
[2] https://www.timothysykes.com/news/iovance-biotherapeutics-inc-iova-news-2025_07_23/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments

No comments yet